Loading patent…
AssigneesThe Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Instituto Carlos Slim De La Salud, A.C.
InventorsSteven Corsello, Ryan Spangler, Rohith Nagari, Todd Golub
Estimating the term…
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and/or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.
A method for selecting a treatment for a subject having a Solute Carrier Family 26 Member 2 (SLC26A2) positive cancer, the method comprising:
A method for selecting a treatment for a subject having a Solute Carrier Family 26 Member 2 (SLC26A2) positive cancer, the method comprising:
A method for selecting a treatment for a subject having a Solute Carrier Family 26 Member 2 (SLC26A2) positive cancer, the method comprising:
Dependencies are inferred from the claim text.